Congressional Democrats Seek DOJ and FTC Investigation into Blood Thinner Price Hikes

June 15, 2022

Johnson & Johnson and Bristol Meyers Squib are facing increasing scrutiny from members of the US Congress after allegations of price-fixing. The two pharma giants’ blood thinners Xarelto and Eliquis have risen in price in tandem, a pricing pattern deemed suspiciously uncompetitive to some congress members and advocates. Sen. Amy Klobuchar (D-Minnesota) and Rep. Katie Porter (D-California) have called for the Department of Justice (DOJ) and Federal Trade Commission (FTC) to investigate the allegations.

According to the congressional leaders, “We are principally concerned that the prices for these products, which are close substitutes for each other, have been raised in lockstep in a manner that seems coordinated to maintain pricing parity. The general lack of competitive behavior exhibited by these drug sellers raises concerns regarding potential unlawful conduct.”

To learn more, click here.

(Source: Fierce Pharma, June 14th, 2022)

Share This Story!